SCHEMBL6353357

SCHEMBL6353357

CCCCP(=O)(O)C(O)CCN

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 3/20 0.57
GABBR1 Q9UBS5 3/20 0.57
GABRR1 P24046 1/20 0.57
CYP1A2 P05177 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TSHR P16473 1/20 0.42
THPO P40225 1/20 0.42
LAP3 P28838 1/20 0.41
FDPS P14324 1/20 0.41
LMNA P02545 1/20 0.41
BLM P54132 1/20 0.41
S1PR2 O95136 5/20 0.41
S1PR1 P21453 5/20 0.41
S1PR3 Q99500 5/20 0.41
S1PR4 O95977 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9416973 0.98 GABBR2 (0.55) GABBR2GABBR1GABRR1CYP1A2MEN1
SCHEMBL6360421 0.89 CYP1A2 (0.53) GABBR2GABBR1GABRR1CYP1A2MEN1
SCHEMBL6358737 0.88 GABBR2 (0.45) GABBR2GABBR1GABRR1CYP1A2MEN1
Hydrochloric Acid SCHEMBL9336338 0.87 CYP1A2 (0.51) GABBR2GABBR1GABRR1CYP1A2MEN1
SCHEMBL6356256 0.81 GABBR2 (0.57) GABBR2GABBR1GABRR1CYP1A2MEN1
SCHEMBL9155392 0.79 GABBR2 (0.55) GABBR2GABBR1GABRR1CYP1A2MEN1
SCHEMBL6354148 0.74 CYP1A2 (0.42) GABBR2GABBR1GABRR1CYP1A2MEN1
Hydrochloric Acid SCHEMBL9336310 0.73 LMNA (0.41) GABBR2GABBR1GABRR1CYP1A2MEN1
Sgs-742 SCHEMBL195133 0.73 GABBR2 (1.00) GABBR2GABBR1GABRR1CYP1A2MEN1
Sgs-742 SCHEMBL6024389 0.71 GABBR2 (0.95) GABBR2GABBR1GABRR1CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020187977-A1 Methods for restoring cognitive function following systemic stress SAEGIS PHARMACEUTICALS, INC. 2002-12-12 US claimed
US-20050222093-A1 Methods for restoring cognitive function following systemic stress PEARLMAN RODNEY 2005-10-06 US disclosed
US-20020187977-A1 Methods for restoring cognitive function following systemic stress SAEGIS PHARMACEUTICALS, INC. 2002-12-12 US disclosed
US-5190933-A Treatment of cognitive and memory disorders CIBA-GEIGY CORPORATION (US) 1993-03-02 US disclosed
US-5064819-A Antidepressants, anxiolytic agents, GABA antagonists CIBA-GEIGY CORPORATION (US) 1991-11-12 US disclosed
US-5051524-A Treatment of a phosphinic acid with an anhydrous protic medium CIBA-GEIGY CORPORATION (US) 1991-09-24 US disclosed
US-5013863-A Learning enhancement CIBA-GEIGY CORPORATION (US) 1991-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222093-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT GABBR2 2093/4885GABBR1 1947/4885GABRR1 420/4885
US-20020187977-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT GABBR2 2093/4885GABBR1 1947/4885GABRR1 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.